{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:37:56Z","timestamp":1790203076430,"version":"4.1.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T00:00:00Z","timestamp":1472428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T00:00:00Z","timestamp":1472428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/leu.2016.246","type":"journal-article","created":{"date-parts":[[2016,8,29]],"date-time":"2016-08-29T06:46:58Z","timestamp":1472453218000},"page":"593-601","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":92,"title":["Treatment and outcome of 2904 CML patients from the EUTOS population-based registry"],"prefix":"10.1038","volume":"31","author":[{"given":"V S","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Baccarani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Hasford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Castagnetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L F","family":"Casado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Turkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Zackova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Zaritskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Simonsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Indrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z","family":"Sninska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Sacha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Bogdanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Griskevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Schubert-Fritschle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Sertic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Guilhot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lejniece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Zupan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Burgstaller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Koskenvesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Everaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Costeas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Lindoerfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Rosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Saussele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Hochhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Hehlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,29]]},"reference":[{"key":"BFleu2016246_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00277-015-2325-z","volume":"94","author":"B Chereda","year":"2015","unstructured":"Chereda B, Melo JV . Natural course and biology of CML. Ann Hematol 2015; 94: 107\u2013121.","journal-title":"Ann Hematol"},{"key":"BFleu2016246_CR2","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","volume":"370","author":"R Hehlmann","year":"2007","unstructured":"Hehlmann R, Hochhaus A, Baccarani M . Chronic myeloid leukaemia. Lancet 2007; 370: 342\u2013350.","journal-title":"Lancet"},{"key":"BFleu2016246_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 2013; 122: 872\u2013884.","journal-title":"Blood"},{"key":"BFleu2016246_CR4","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3324\/haematol.2010.032979","volume":"96","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Grimwade D, Simonsson B, Apperley J, Baccarani M, Barbui T et al. The European LeukemiaNet: achievements and perspectives. Haematologica 2011; 96: 156\u2013162.","journal-title":"Haematologica"},{"key":"BFleu2016246_CR5","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood-2013-04-495598","volume":"122","author":"M Hoglund","year":"2013","unstructured":"Hoglund M, Sandin F, Hellstrom K, Bjoreman M, Bjorkholm M, Brune M et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. Blood 2013; 122: 1284\u20131292.","journal-title":"Blood"},{"key":"BFleu2016246_CR6","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/ejh.12695","volume":"97","author":"N Thielen","year":"2016","unstructured":"Thielen N, Visser O, Ossenkoppele G, Janssen J . Chronic myeloid leukaemia in The Netherlands: a population-based study on incidence, treatment and survival in 3,585 patients from 1989\u20132012. Eur J Haematol 2016; 97: 145\u2013154.","journal-title":"Eur J Haematol"},{"key":"BFleu2016246_CR7","doi-asserted-by":"publisher","first-page":"e004266","DOI":"10.1136\/bmjopen-2013-004266","volume":"4","author":"AG Smith","year":"2014","unstructured":"Smith AG, Painter D, Howell DA, Evans P, Smith G, Patmore R et al. Determinants of survival in patients with chronic myeloid leukaemia treated in the new era of oral therapy: findings from a UK population-based patient cohort. BMJ Open 2014; 4: e004266.","journal-title":"BMJ Open"},{"key":"BFleu2016246_CR8","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","volume":"108","author":"M Baccarani","year":"2006","unstructured":"Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809\u20131820.","journal-title":"Blood"},{"key":"BFleu2016246_CR9","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/leu.2015.73","volume":"29","author":"VS Hoffmann","year":"2015","unstructured":"Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia 2015; 29: 1336\u20131343.","journal-title":"Leukemia"},{"key":"BFleu2016246_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1182\/blood-2010-12-319038","volume":"118","author":"J Hasford","year":"2011","unstructured":"Hasford J, Baccarani M, Hoffmann V, Guilhot J, Saussele S, Rosti G et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 2011; 118: 686\u2013692.","journal-title":"Blood"},{"key":"BFleu2016246_CR11","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/leu.2013.171","volume":"27","author":"VS Hoffmann","year":"2013","unstructured":"Hoffmann VS, Baccarani M, Lindoerfer D, Castagnetti F, Turkina A, Zaritsky A et al. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib. Leukemia 2013; 27: 2016\u20132022.","journal-title":"Leukemia"},{"key":"BFleu2016246_CR12","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/leu.2015.261","volume":"30","author":"M Pfirrmann","year":"2016","unstructured":"Pfirrmann M, Baccarani M, Saussele S, Guilhot J, Cervantes F, Ossenkoppele G et al. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia. Leukemia 2016; 30: 48\u201356.","journal-title":"Leukemia"},{"key":"BFleu2016246_CR13","volume-title":"The Statistical Analysis of Failure Time Data","author":"JD Kalbfleisch","year":"2011","unstructured":"Kalbfleisch JD, Prentice RL . The Statistical Analysis of Failure Time Data, vol. 36. Wiley: New York, NY, USA, 2011."},{"key":"BFleu2016246_CR14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1214\/aos\/1176350951","volume":"16","author":"RJ Gray","year":"1988","unstructured":"Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141\u20131154.","journal-title":"Ann Stat"},{"key":"BFleu2016246_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1038\/leu.2015.152","volume":"29","author":"F Castagnetti","year":"2015","unstructured":"Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F et al. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. Leukemia 2015; 29: 1823\u20131831.","journal-title":"Leukemia"},{"issue":"Suppl 2","key":"BFleu2016246_CR16","doi-asserted-by":"publisher","first-page":"S159","DOI":"10.1007\/s00277-015-2324-0","volume":"94","author":"S Saussele","year":"2015","unstructured":"Saussele S, Silver RT . Management of chronic myeloid leukemia in blast crisis. Ann Hematol 2015; 94 (Suppl 2): S159\u2013165.","journal-title":"Ann Hematol"},{"key":"BFleu2016246_CR17","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994\u20131004.","journal-title":"N Engl J Med"},{"key":"BFleu2016246_CR18","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","volume":"362","author":"G Saglio","year":"2010","unstructured":"Saglio G, Kim D-W, Issaragrisil S, le Coutre P, Etienne G, Lobo C et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251\u20132259.","journal-title":"N Engl J Med"},{"key":"BFleu2016246_CR19","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","volume":"30","author":"A Hochhaus","year":"2016","unstructured":"Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G et al. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. Leukemia 2016; 30: 57\u201364.","journal-title":"Leukemia"},{"key":"BFleu2016246_CR20","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","volume":"362","author":"H Kantarjian","year":"2010","unstructured":"Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260\u20132270.","journal-title":"N Engl J Med"},{"key":"BFleu2016246_CR21","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","volume":"119","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood 2012; 119: 1123\u20131129.","journal-title":"Blood"},{"key":"BFleu2016246_CR22","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S, Leitner A, Muller MC, Pletsch N et al. Tolerability-adapted imatinib 800\u2009mg\/d versus 400\u2009mg\/d versus 400\u2009mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 2011; 29: 1634\u20131642.","journal-title":"J Clin Oncol"},{"key":"BFleu2016246_CR23","doi-asserted-by":"publisher","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","volume":"30","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kim DW, Kantarjian HM, Brummendorf TH, Dyagil I, Griskevicius L et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol 2012; 30: 3486\u20133492.","journal-title":"J Clin Oncol"},{"key":"BFleu2016246_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"JE Cortes","year":"2010","unstructured":"Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW et al. Phase III, randomized, open-label study of daily imatinib mesylate 400\u2009mg versus 800\u2009mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 2010; 28: 424\u2013430.","journal-title":"J Clin Oncol"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016246","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016246.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T16:25:22Z","timestamp":1648743922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,29]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFleu2016246"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.246","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,29]]},"assertion":[{"value":"4 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VSH, MB, and JH receive research funding from Novartis. FC has a consulting role and receives honoraria from Novartis, BMS, ARIAD and Pfizer. FR receives honoraria from BMS and has a consulting role at Novartis. LFC has a consulting role and receives funding for clinical research from Novartis, BMS and Pfizer. AT has a consulting role at Novartis, BMS and Pfizer. DZ receives funding of travel, accommodations or expenses from Novartis and BMS. AZ has a consulting or advisory role at and participated in a speakers\u2019 bureau for Novartis and received research funding from BMS. BS has a consulting or advisory role at BMS. ZS has a consulting or advisory role at Novartis. TS has a consulting role at Novartis, BMS, Adamed and Angelini. RC has had research funding from Novartis, Bristol-Myers-Squibb and Pfizer, and has been on the speakers bureau of Novartis and Pfizer in the past 5 years. AB has participated in a speakers\u2019 bureau and received research support from Novartis Pharma Services\/Office in Serbia via the patient assistant support program. AH participated in a speakers\u2019 bureau for Novartis and BMS, receives research funding and funding of travel, accommodations or expenses from Novartis and BMS, and provides expert testimony for Novartis and BMS. LG receives research grants from Novartis. SB receives honoraria from Novartis, Celgene and AOP, has a consulting or advisory role at Novartis and Celgene and receives funding of travel, accommodations or expenses from Novartis and AOP. PK has a consulting or advisory role at GSK, BMS and Novartis, receives funding from Novartis, provides expert testimony for Pfizer and Novartis and receives funding of travel, accommodations or expenses from BMS and Ariad. DL receives research funding from Novartis. SS has received research support from Novartis and BMS and receives honoraria from Novartis, BMS, Ariad and Pfizer. AH has received research funding from Novartis. RH has received research support from Novartis, Consultant for BMS. KI, GSF, DS, JG, SL, IZ, HE, PC, GO and GR have no conflict of financial interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}